These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20018309)

  • 41. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary symptoms and prostate cancer treatment.
    Health News; 2004 Jun; 10(6):2. PubMed ID: 15199892
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial comment on: continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study.
    Albrecht W
    Eur Urol; 2008 Aug; 54(2):390-1. PubMed ID: 18339476
    [No Abstract]   [Full Text] [Related]  

  • 44. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 45. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
    [No Abstract]   [Full Text] [Related]  

  • 46. Endocrine manipulation of human prostatic cancer: state of the art.
    Serio M; Calabresi E; Salerno R
    J Chemother; 1989 Jul; 1(4 Suppl):1227-30. PubMed ID: 16312845
    [No Abstract]   [Full Text] [Related]  

  • 47. Treatment of advanced cancer of the prostate.
    Orovan WL
    Can J Surg; 1989 Sep; 32(5):315-6. PubMed ID: 2670160
    [No Abstract]   [Full Text] [Related]  

  • 48. Combined modality treatment in the management of high-risk prostate cancer.
    Stock RG; Cahlon O; Cesaretti JA; Kollmeier MA; Stone NN
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1352-9. PubMed ID: 15275720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Celecoxib to decrease urinary retention associated with prostate brachytherapy.
    Feigenberg SJ; Wolk KL; Yang CH; Morris CG; Zlotecki RA
    Brachytherapy; 2003; 2(2):103-7. PubMed ID: 15062148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New aspects of anti-androgenic therapy of prostatic cancer].
    Portnoĭ AS
    Urol Nefrol (Mosk); 1985; (3):69-73. PubMed ID: 3892832
    [No Abstract]   [Full Text] [Related]  

  • 51. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
    Sylvester J; Blasko JC; Grimm PD; Meier R; Cavanagh W
    Mol Urol; 2000; 4(3):155-9;discussion 161. PubMed ID: 11062369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Hormone therapy for prostate cancer].
    Théodore C
    Bull Cancer; 2004 Jan; 91(1):69-74. PubMed ID: 14975807
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation.
    Stone NN; Stock RG; Unger P
    Mol Urol; 2000; 4(3):163-8;discussion 169-70. PubMed ID: 11062370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guidelines on the management of prostate cancer.
    Ago CT
    Clin Oncol (R Coll Radiol); 1999; 11(5):361. PubMed ID: 10591828
    [No Abstract]   [Full Text] [Related]  

  • 56. Compliance with hormonal treatment for prostate cancer.
    Kaisary AV
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):359-66. PubMed ID: 8696636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Endocrine therapy for prostate cancer.
    Labrie F
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complete hormonal blockage--antiandrogens.
    Bierkens AF; Debruyne FM
    Acta Urol Belg; 1996 May; 64(2):77-9. PubMed ID: 8701818
    [No Abstract]   [Full Text] [Related]  

  • 60. The current state of hormonal therapy for prostate cancer.
    Hellerstedt BA; Pienta KJ
    CA Cancer J Clin; 2002; 52(3):154-79. PubMed ID: 12018929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.